Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated strong performance metrics, particularly within its plasma segment, which experienced a 20.2% organic growth rate, underscoring the company's ability to capture market share despite competitive pressures. Additionally, the adjusted operating margin in the plasma business increased by 60 basis points to 36.2%, reflecting improved profitability across all segments. The company has also revised its expectations for free cash flow upwards to a range of $200-220 million, indicating enhanced financial health and operational efficiency.

Haemonetics Corp reported a significant decline in revenue, with a 19.6% drop as reported, largely attributed to divestitures, despite showing a modest 2.8% organic growth. The company faces a challenging environment, indicated by a forecast for FY/26 that anticipates a reported revenue decline of 1% to 4%, alongside an expected organic growth rate of only 7% to 10%, suggesting a potential mismatch in growth drivers. Furthermore, the interventional technologies segment displayed persistent weakness, with an 11.6% organic decline, raising concerns over the sustainability of revenue streams and overall financial performance.